Which has preferable earnings and valuation, GSK or MRK?

Merck & Co., Inc. has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.33 $7.54B $3.20 15.48 Merck & Co., Inc. $65.01B 5.15 $18.25B $1.25 108.62

Is GSK or MRK more profitable?

GSK has a net margin of 14.56% compared to Merck & Co., Inc.'s net margin of 4.77%. GSK's return on equity of 43.23% beat Merck & Co., Inc.'s return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Merck & Co., Inc. 4.77% 16.73% 6.13%

Does the media favor GSK or MRK?

In the previous week, Merck & Co., Inc. had 53 more articles in the media than GSK. MarketBeat recorded 57 mentions for Merck & Co., Inc. and 4 mentions for GSK. Merck & Co., Inc.'s average media sentiment score of 0.93 beat GSK's score of 0.45 indicating that Merck & Co., Inc. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Merck & Co., Inc. 36 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, NVS or GSK?

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.28 $13.98B $6.63 22.78 GSK $43.07B 2.33 $7.54B $3.20 15.48

Is NVS or GSK more profitable?

Novartis has a net margin of 23.29% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 23.29% 38.56% 14.47% GSK 14.56% 43.23% 11.60%

Does the media refer more to NVS or GSK?

In the previous week, Novartis had 6 more articles in the media than GSK. MarketBeat recorded 10 mentions for Novartis and 4 mentions for GSK. Novartis' average media sentiment score of 0.84 beat GSK's score of 0.45 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GSK 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, AZN or GSK?

Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.13 $10.23B $6.69 23.38 GSK $43.07B 2.33 $7.54B $3.20 15.48

Is AZN or GSK more profitable?

Astrazeneca has a net margin of 17.02% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% GSK 14.56% 43.23% 11.60%

Does the media favor AZN or GSK?

In the previous week, Astrazeneca had 9 more articles in the media than GSK. MarketBeat recorded 13 mentions for Astrazeneca and 4 mentions for GSK. Astrazeneca's average media sentiment score of 0.63 beat GSK's score of 0.45 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive GSK 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, NVO or GSK?

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.38 $15.51B $4.09 11.23 GSK $43.07B 2.33 $7.54B $3.20 15.48

Is NVO or GSK more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to GSK's net margin of 14.56%. Novo Nordisk A/S's return on equity of 61.20% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 35.36% 61.20% 21.49% GSK 14.56% 43.23% 11.60%

Does the media refer more to NVO or GSK?

In the previous week, Novo Nordisk A/S had 43 more articles in the media than GSK. MarketBeat recorded 47 mentions for Novo Nordisk A/S and 4 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.56 beat GSK's score of 0.45 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 20 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Positive GSK 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PFE or GSK?

Pfizer currently has a consensus target price of $28.28, suggesting a potential upside of 5.62%. GSK has a consensus target price of $53.00, suggesting a potential upside of 6.98%. Given GSK's higher probable upside, analysts plainly believe GSK is more favorable than Pfizer. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pfizer 2 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.19 GSK 2 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.10

Which has preferable earnings & valuation, PFE or GSK?

Pfizer has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.44 $7.77B $0.76 35.23 GSK $43.07B 2.33 $7.54B $3.20 15.48

Is PFE or GSK more profitable?

GSK has a net margin of 14.56% compared to Pfizer's net margin of 6.80%. GSK's return on equity of 43.23% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 6.80% 19.63% 8.46% GSK 14.56% 43.23% 11.60%

Does the media refer more to PFE or GSK?

In the previous week, Pfizer had 52 more articles in the media than GSK. MarketBeat recorded 56 mentions for Pfizer and 4 mentions for GSK. Pfizer's average media sentiment score of 0.95 beat GSK's score of 0.45 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 30 Very Positive mention(s) 16 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive GSK 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GSK (GSK) Competitors

$49.54 -0.91 (-1.80%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$49.53 -0.01 (-0.03%)

As of 08/14/2026 07:57 PM Eastern

Compare

GSK vs. MRK, NVS, AZN, NVO, and PFE

Should you buy GSK stock or one of its competitors? GSK's main competitors and comparable companies include Merck & Co., Inc. (MRK), Novartis (NVS), Astrazeneca (AZN), Novo Nordisk A/S (NVO), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GSK compare to Merck & Co., Inc.?

GSK (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

15.7% of GSK shares are owned by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Merck & Co., Inc. has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.33	$7.54B	$3.20	15.48
Merck & Co., Inc.	$65.01B	5.15	$18.25B	$1.25	108.62

GSK has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

GSK has a net margin of 14.56% compared to Merck & Co., Inc.'s net margin of 4.77%. GSK's return on equity of 43.23% beat Merck & Co., Inc.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Merck & Co., Inc.	4.77%	16.73%	6.13%

In the previous week, Merck & Co., Inc. had 53 more articles in the media than GSK. MarketBeat recorded 57 mentions for Merck & Co., Inc. and 4 mentions for GSK. Merck & Co., Inc.'s average media sentiment score of 0.93 beat GSK's score of 0.45 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Merck & Co., Inc.	36 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.6%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.5%. GSK pays out 55.9% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 272.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has raised its dividend for 14 consecutive years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK currently has a consensus target price of $53.00, indicating a potential upside of 6.98%. Merck & Co., Inc. has a consensus target price of $135.50, indicating a potential downside of 0.20%. Given GSK's higher probable upside, research analysts clearly believe GSK is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.68

Summary

GSK and Merck & Co., Inc. tied by winning 10 of the 20 factors compared between the two stocks.

How does GSK compare to Novartis?

Novartis (NYSE:NVS) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Novartis has a net margin of 23.29% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	23.29%	38.56%	14.47%
GSK	14.56%	43.23%	11.60%

Novartis presently has a consensus price target of $141.20, suggesting a potential downside of 6.50%. GSK has a consensus price target of $53.00, suggesting a potential upside of 6.98%. Given GSK's higher probable upside, analysts clearly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10

In the previous week, Novartis had 6 more articles in the media than GSK. MarketBeat recorded 10 mentions for Novartis and 4 mentions for GSK. Novartis' average media sentiment score of 0.84 beat GSK's score of 0.45 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novartis has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

13.1% of Novartis shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.28	$13.98B	$6.63	22.78
GSK	$43.07B	2.33	$7.54B	$3.20	15.48

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.6%. Novartis pays out 46.5% of its earnings in the form of a dividend. GSK pays out 55.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novartis beats GSK on 13 of the 19 factors compared between the two stocks.

How does GSK compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Astrazeneca has a net margin of 17.02% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
GSK	14.56%	43.23%	11.60%

In the previous week, Astrazeneca had 9 more articles in the media than GSK. MarketBeat recorded 13 mentions for Astrazeneca and 4 mentions for GSK. Astrazeneca's average media sentiment score of 0.63 beat GSK's score of 0.45 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
GSK	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.13	$10.23B	$6.69	23.38
GSK	$43.07B	2.33	$7.54B	$3.20	15.48

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Astrazeneca has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

Astrazeneca currently has a consensus target price of $211.00, indicating a potential upside of 34.93%. GSK has a consensus target price of $53.00, indicating a potential upside of 6.98%. Given Astrazeneca's stronger consensus rating and higher probable upside, equities research analysts clearly believe Astrazeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.6%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. GSK pays out 55.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Astrazeneca beats GSK on 13 of the 19 factors compared between the two stocks.

How does GSK compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Novo Nordisk A/S has a net margin of 35.36% compared to GSK's net margin of 14.56%. Novo Nordisk A/S's return on equity of 61.20% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	61.20%	21.49%
GSK	14.56%	43.23%	11.60%

In the previous week, Novo Nordisk A/S had 43 more articles in the media than GSK. MarketBeat recorded 47 mentions for Novo Nordisk A/S and 4 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.56 beat GSK's score of 0.45 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	20 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Positive
GSK	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.38	$15.51B	$4.09	11.23
GSK	$43.07B	2.33	$7.54B	$3.20	15.48

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.6%. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. GSK pays out 55.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S presently has a consensus target price of $64.94, indicating a potential upside of 41.44%. GSK has a consensus target price of $53.00, indicating a potential upside of 6.98%. Given Novo Nordisk A/S's stronger consensus rating and higher possible upside, research analysts clearly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	0 Sell rating(s)	16 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10

Novo Nordisk A/S has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

Summary

Novo Nordisk A/S beats GSK on 15 of the 19 factors compared between the two stocks.

How does GSK compare to Pfizer?

Pfizer (NYSE:PFE) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

In the previous week, Pfizer had 52 more articles in the media than GSK. MarketBeat recorded 56 mentions for Pfizer and 4 mentions for GSK. Pfizer's average media sentiment score of 0.95 beat GSK's score of 0.45 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	30 Very Positive mention(s)	16 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.4%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.6%. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK pays out 55.9% of its earnings in the form of a dividend. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

GSK has a net margin of 14.56% compared to Pfizer's net margin of 6.80%. GSK's return on equity of 43.23% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
GSK	14.56%	43.23%	11.60%

Pfizer currently has a consensus target price of $28.28, suggesting a potential upside of 5.62%. GSK has a consensus target price of $53.00, suggesting a potential upside of 6.98%. Given GSK's higher probable upside, analysts plainly believe GSK is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.6% of Pfizer shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pfizer has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.44	$7.77B	$0.76	35.23
GSK	$43.07B	2.33	$7.54B	$3.20	15.48

Pfizer has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

Summary

Pfizer beats GSK on 11 of the 19 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GSK vs. The Competition

Export

Metric	GSK	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$100.16B	$11.81B	$7.04B	$24.33B
Dividend Yield	3.61%	2.70%	2.57%	3.68%
P/E Ratio	15.49	779.99	271.54	30.85
Price / Sales	2.33	948.84	673.88	17.93
Price / Cash	8.25	89.04	75.70	32.61
Price / Book	4.35	11.60	12.92	6.82
Net Income	$7.54B	$2.77B	$3.45B	$1.06B
7 Day Performance	-6.67%	0.18%	1.17%	0.55%
1 Month Performance	-6.11%	0.70%	2.18%	2.70%
1 Year Performance	26.06%	145.73%	62.39%	19.14%

GSK Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GSK GSK	3.546 of 5 stars	$49.54 -1.8%	$53.00 +7.0%	+26.1%	$100.16B	$43.07B	15.49	66,841	Dividend Cut Gap Down
MRK Merck & Co., Inc.	4.3319 of 5 stars	$130.49 -0.3%	$135.11 +3.5%	+61.0%	$322.44B	$65.01B	104.44	75,000	Trending News Analyst Forecast Insider Trade Analyst Revision
NVS Novartis	3.4664 of 5 stars	$154.71 -1.3%	$141.20 -8.7%	+21.6%	$295.43B	$54.53B	23.35	75,267	Analyst Revision
AZN Astrazeneca	4.8691 of 5 stars	$158.94 -1.8%	$211.00 +32.8%	-1.2%	$246.57B	$58.74B	23.76	96,100	Analyst Revision
NVO Novo Nordisk A/S	4.6737 of 5 stars	$47.30 -0.9%	$65.81 +39.1%	-12.4%	$211.40B	$46.80B	11.58	69,505	Trending News Analyst Upgrade Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GSK) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Competitors

GSK vs. MRK, NVS, AZN, NVO, and PFE

How does GSK compare to Merck & Co., Inc.?

Summary

How does GSK compare to Novartis?

Summary

How does GSK compare to Astrazeneca?

Summary

How does GSK compare to Novo Nordisk A/S?

Summary

How does GSK compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK vs. The Competition

GSK Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GSK (GSK) Competitors

GSK vs. MRK, NVS, AZN, NVO, and PFE

How does GSK compare to Merck & Co., Inc.?

Do insiders and institutionals believe in GSK or MRK?

Which has preferable earnings and valuation, GSK or MRK?

Which has more volatility & risk, GSK or MRK?

Is GSK or MRK more profitable?

Does the media favor GSK or MRK?

Is GSK or MRK a better dividend stock?

Do analysts rate GSK or MRK?

Summary

How does GSK compare to Novartis?

Is NVS or GSK more profitable?

Do analysts rate NVS or GSK?

Does the media refer more to NVS or GSK?

Which has more volatility and risk, NVS or GSK?

Do insiders & institutionals believe in NVS or GSK?

Which has preferable earnings and valuation, NVS or GSK?

Is NVS or GSK a better dividend stock?

Summary

How does GSK compare to Astrazeneca?

Is AZN or GSK more profitable?

Does the media favor AZN or GSK?

Which has preferable valuation and earnings, AZN or GSK?

Do institutionals & insiders hold more shares of AZN or GSK?

Which has more risk & volatility, AZN or GSK?

Do analysts prefer AZN or GSK?

Is AZN or GSK a better dividend stock?

Summary

How does GSK compare to Novo Nordisk A/S?

Is NVO or GSK more profitable?

Does the media refer more to NVO or GSK?

Which has better earnings & valuation, NVO or GSK?

Do institutionals and insiders believe in NVO or GSK?

Is NVO or GSK a better dividend stock?

Do analysts prefer NVO or GSK?

Which has more volatility & risk, NVO or GSK?

Summary

How does GSK compare to Pfizer?

Does the media refer more to PFE or GSK?

Is PFE or GSK a better dividend stock?

Is PFE or GSK more profitable?

Do analysts prefer PFE or GSK?

Do insiders & institutionals have more ownership in PFE or GSK?

Which has preferable earnings & valuation, PFE or GSK?

Which has more volatility and risk, PFE or GSK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK vs. The Competition

GSK Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools